Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Sarcoma, Kaposi 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Head and Neck Neoplasms 1HIV Infections 1Carcinoma, Renal Cell 1Carcinoma, Adenoid Cystic 1AIDS-related Kaposi sarcoma 1AIDS-Related Opportunistic Infections 1

Interventions

Papillomavirus Vaccines 2Imiquimod 2GX-188 vaccine 2Celecoxib 24,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone 2poly(gamma-glutamic acid) 1pembrolizumab 1nimotuzumab 1epigallocatechin gallate 1artesunic acid 1artemisinin 1Sutures 1Progesterone 1Pemetrexed 1Omeprazole 1Ointments 1Ocoxin 1Nelfinavir 1Lighting 1Indomethacin 1IRX 2 1Hepatitis B Vaccines 1Geritol 1GPI0100 1Folic Acid 1Eflornithine 1Cyclophosphamide 1Conization 1Cisplatin 1Chemoprevention 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Dysplasia × Nelfinavir × Clear all
NCT01925378 2020-11-12

A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia

The University of Texas Health Science Center, Houston

Phase 2 Withdrawn
Gynecologic

Uterine Cervical Dysplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡